Predict your next investment

Corporation
HEALTHCARE | Drug Discovery
ivericbio.com

See what CB Insights has to offer

Stage

IPO | IPO

Total Raised

$116M

Date of IPO

9/25/2013

Market Cap

0.64B

Stock Price

8.95

About IVERIC bio

IVERIC bio operates as a biopharmaceutical company. The company develops treatments for patients with orphan inherited retinal diseases with significant unmet medical needs. It is based in New York City, New York.

IVERIC bio Headquarter Location

One Penn Plaza Suite 3520

New York, New York, 10119,

United States

212-845-8200

Latest IVERIC bio News

Iveric Bio Appoints Christopher Simms as Chief Commercial Officer

Jul 20, 2021

Iveric bio announced the appointment of Christopher Simms to Senior Vice President and Chief Commercial Officer, effective August 2, 2021. Mr. Simms joins Iveric Bio from Novartis, where he managed commercial operations for the U.S. Ophthalmics Franchise, launching Beovu (brolucizumab injection) for wet age-related macular degeneration (AMD). Before Novartis, he served as marketing lead for the Genentech ophthalmology business which included creating a new brand positioning and launching a new campaign for Lucentis (ranibizumab injection). “In this newly created position, Chris’s responsibilities include developing and implementing the company’s commercial strategy and establishing our commercial infrastructure as we complete our GATHER2 clinical trial, prepare for a potential new drug application (NDA) and begin to prepare for a potential launch of Zimura (avacincaptad pegol) for the treatment of geographic atrophy secondary to AMD,” Glenn P. Sblendorio, Chief Executive Officer of Iveric Bio, said in a company news release. “We are excited about a potential launch of Zimura and our strategy to develop multiple, complementary assets to establish an AMD franchise. We believe Chris’s deep understanding of the retinal space and highly accomplished commercial experience with launching retinal products of blockbuster potential will serve us well.” “It is exciting to see the advances that Iveric Bio has made,” Mr. Simms said in the news release. “I believe the company is well positioned as it begins to pivot to a commercial organization that brings treatments to patients suffering from devastating sight threatening diseases. I am thrilled to join the management team at Iveric Bio and look forward to building and leading a commercial organization that has a positive impact on patients and the development of our products.”

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing IVERIC bio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

IVERIC bio is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

E

Eye Health

711 items

B

Biopharmaceuticals

5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

IVERIC bio Patents

IVERIC bio has filed 18 patents.

The 3 most popular patent topics include:

  • Addition reactions
  • Coupling reactions
  • Rearrangement reactions
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/17/2009

4/1/2014

Monoclonal antibodies, Experimental cancer drugs, Indoles, Clusters of differentiation, Transcription factors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/17/2009

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

4/1/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Monoclonal antibodies, Experimental cancer drugs, Indoles, Clusters of differentiation, Transcription factors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.